Maze Therapeutics MZE829-201: An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Clinical Trial Grant
Administered By
Medicine, Nephrology
Awarded By
Maze Therapeutics
Start Date
April 1, 2025
End Date
December 31, 2030
Administered By
Medicine, Nephrology
Awarded By
Maze Therapeutics
Start Date
April 1, 2025
End Date
December 31, 2030